BryceTech has secured three multi-year prime contracts from the U.S. Department of Defense, valued at approximately $70 million over five years. The work supports the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) and reinforces BryceTech's role in delivering critical capabilities to protect the Joint Force.

JPEO-CBRND delivers integrated CBRN defense capabilities across all-domain operations, enabling the Joint Force to operate, fight, and win in contested environments. Under these awards, BryceTech will deploy about 50 full-time professionals with acquisition, scientific, technical, and programmatic expertise. The team will accelerate medical countermeasure development, strengthen enterprise decision-support systems, and enhance operational coordination across research, logistics, quality assurance, and program execution. The contracts support three key offices:

• JPL Enabling Biotechnologies (JPL-EB): Advances development, manufacturing, testing, and deployment of lifesaving medical countermeasures.
• JPM CBRN Integration: Delivers enterprise CBRN threat warning, hazard prediction, and decision-support systems to safeguard the Joint Force.
• JPM CBRN Medical: Fields FDA-approved diagnostics, therapeutics, and vaccines against evolving CBRN threats.

The work, awarded under the General Services Administration's OASIS+ contract vehicle, ensures continuity of services for critical national security missions.

"Protecting the Joint Warfighter depends on advancing and integrating CBRN defense capabilities that allow our forces to operate, fight, and win," said Jeff Mujsce, Chief Growth Officer at BryceTech. "These three offices are central to developing, sustaining, and improving those capabilities. BryceTech is proud to provide the dedicated, highly qualified staff needed to strengthen programs, enhance integration, and deliver results where they matter most."

 

Source: prnewswire.com

Report Abuse